Tylenol is a widely recognized over-the-counter (OTC) pharmaceutical brand known for its pain-relieving and fever-reducing properties. Its active ingredient is acetaminophen (paracetamol in many regions). Tylenol products are marketed under McNeil Consumer Healthcare, a division of Kenvue Inc.
The brand was first introduced in 1955 by McNeil Laboratories in the United States. Over the decades, Tylenol has become a leading household name in healthcare, trusted by millions worldwide for common ailments like headaches, flu, colds, and muscle pain.
As of September 2025, Tylenol is managed under Kenvue Inc., headquartered in Skillman, New Jersey, USA, with Thibaut Mongon serving as the company’s CEO since the spin-off from Johnson & Johnson in 2023.
Ownership Status of Tylenol
There is no single private owner of Tylenol. Since Tylenol is a brand owned by Kenvue Inc., a publicly traded company, its ownership is distributed among institutional investors, mutual funds, and individual shareholders.
Ownership percentages change over time depending on stock market activity and SEC filings such as 13F and 13G.
Major Shareholders of Kenvue Inc. (which owns Tylenol)
| Shareholder / Entity | Ownership Percentage | Notes |
|---|---|---|
| Vanguard Group Inc. | ~8% | Reported in recent SEC 13F filings; passive index investor. |
| BlackRock Inc. | ~7% | One of the world’s largest asset managers; invests through ETFs and funds. |
| State Street Corporation | ~4% | Passive institutional investor. |
| Johnson & Johnson (initially) | Legacy Stake | Retained a partial stake after Kenvue’s spin-off in 2023. |
Note: The remaining shares are widely held by other institutional investors, mutual funds, and retail shareholders.
Key Shareholder Highlights
Tylenol’s parent company Kenvue Inc. has a shareholder base consisting mainly of large passive investors:
- Vanguard Group holds around 8%, reflecting its role as a leading index fund manager.
- BlackRock owns about 7%, primarily through ETFs.
- State Street holds roughly 4%, making up another part of the “Big Three” index fund managers.
These investors are generally passive, meaning they do not directly influence Tylenol’s day-to-day operations but can influence corporate governance matters.
Recent Developments in Ownership
- In May 2023, Johnson & Johnson completed the spin-off of its consumer health division, creating Kenvue Inc., the new owner of Tylenol.
- Johnson & Johnson initially retained a stake in Kenvue but has since reduced its holding through share distributions.
- As of 2025, Kenvue operates fully independently as a public company, with its own board and executive leadership.
FAQs
1. Who is the current owner of Tylenol?
Tylenol is owned by Kenvue Inc., a publicly traded consumer health company.
2. Is Tylenol publicly traded or privately owned?
Tylenol itself is not traded. Its parent company, Kenvue Inc., is publicly traded on the New York Stock Exchange (NYSE) under the ticker KVUE.
3. Who founded Tylenol?
Tylenol was first introduced in 1955 by McNeil Laboratories, which was later acquired by Johnson & Johnson in 1959.
4. Has the ownership changed recently?
Yes. In 2023, Johnson & Johnson spun off its consumer health business into Kenvue Inc., making Kenvue the new parent company of Tylenol.
Discover more from Who Is The Owner Of
Subscribe to get the latest posts sent to your email.